Treatment of node-positive endometrial cancer: chemotherapy, radiation, immunotherapy, and targeted therapy.

ABSTRACT:

Opinion statement

The standard of treatment for node-positive endometrial cancer (FIGO Stage IIIC) in North America has been systemic therapy with or without additional external beam radiation therapy (RT) given as pelvic or extended field RT. However, this treatment paradigm is rapidly evolving with improvements in systemic chemotherapy, the emergence of targeted therapies, and improved molecular characterization of these tumors. The biggest question facing providers regarding management of stage IIIC endometrial cancer at this time is: what is the best management strategy to use with regard to combinations of cytotoxic chemotherapy, immunotherapy, other targeted therapeutics, and radiation that will maximize clinical benefit and minimize toxicities for the best patient outcomes?

SUBMITTER: Tubridy EA 

PROVIDER: S-EPMC10894756 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature